The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United Kingdom's Interventional Procedures Programme at the National Institute for Health and Care Excellence ("NICE") has issued guidance supporting the implantation of the Neovasc Reducer™ ("Reducer") in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest...
2021-11-24 9:29 AM EST
Neovasc Announces Third Quarter 2021 Financial Results and Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2021. Third Quarter HighlightsStrong progress against all three value creation strategies.Generated record revenue of approximately $703,000 in the quarter, up 12% from the same period in 2020.Advanced strategic focus to obtain additional reimbursement for the Neovasc...
2021-11-09 4:05 PM EST
Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on November 9, 2021.Interested parties may access the conference call by dialing (877)-407-9208 or...
2021-11-01 9:05 AM EDT
Neovasc Reducer(TM) Featured in Polish Heart Journal
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 21, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") is featured in an article published in the latest issue of the Polish Heart Journal. Entitled "Efficacy of Coronary Sinus Reducer Implantation in Patients with Chronic Total Occlusion of the Right Coronary Artery," the article's first author is Miha Mrak, M.D., University Medical Centre...
2021-10-21 9:05 AM EDT
Neovasc REDUCER-I Study Published in EuroIntervention Journal
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)" in the September 2021 issue of the journal EuroIntervention.The article's lead authors are Stefan Verheye, MD, PhD, Cardiovascular Center, ZNA...
2021-09-28 9:05 AM EDT
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 23, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021. Bill Little, Neovasc's Chief Operating Officer, will give a presentation on Wednesday, September 29 at 4:00 pm EDT. A link to the live webcast of the presentation will be available in the...
2021-09-23 9:05 AM EDT
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received FDA approval for the Investigational Device Exemption ("IDE") regarding the COSIRA-II IDE Clinical Trial. Following multiple discussions with FDA over the past several months, the approved protocol for the COSIRA-II study is designed to answer key questions arising from the October 2020 Circulatory...
2021-09-16 9:05 AM EDT
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A pre-recorded company presentation will be available beginning at 7:00 am EDT on September 13 through the conference website and the Investor Relations section of the Neovasc website...
2021-08-30 4:05 PM EDT
Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 17, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA). Following multiple productive discussions with FDA over the past several months, the protocol for the previously approved COSIRA-II study has been supplemented in consideration of...
2021-08-17 9:05 AM EDT
Neovasc Announces Second Quarter 2021 Financial Results
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 10, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2021.Second Quarter HighlightsGenerated revenue of approximately $633,000 in the quarter, up 123% from the same period in 2020, and a sequential 40% increase from Q1 2021.Streamlined strategic focus to pursue three value-creation strategies around Reducer and Tiara TA,...
2021-08-10 4:05 PM EDT
Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc's President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 pm EDT.Interested parties may access the conference call by dialing (877)-407-9208 or (201)-493-6784 (International) and...
2021-07-27 9:05 AM EDT
Neovasc Announces New Appointments in Regulatory and Clinical Leadership
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 13, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has appointed Lisa Becker as Vice President, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as Vice President, Clinical Affairs."Neovasc's Regulatory and Clinical teams will be well strengthened with the additions of Lisa and Sarah, who bring tremendous experience in regulatory and clinical affairs to the...
2021-07-13 9:05 AM EDT
Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 18, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study" in the International Journal of Cardiology.The article, authored by Francesco Ponticelli, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes long-term outcomes of patients...
2021-06-18 9:05 AM EDT
Neovasc Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024, focusing investments on near term value drivers, and more deeply reviewing the Company's core business activities.Neovasc Reducer™The Company is focused...
2021-06-10 3:29 PM EDT
Neovasc Reducer System Receives First National Reimbursement in Europe
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 7, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Neovasc Reducer® ("Reducer") system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue.The National Health Service England (NHS England) has a nationwide purchase and supply system for specific categories of high-cost...
2021-06-07 9:05 AM EDT
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the "Meeting").At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen to serve in office...
2021-06-03 4:52 PM EDT
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 25, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to...
2021-05-25 4:05 PM EDT
Neovasc Provides Update on German Litigation
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 20, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the court had found that Edwards Lifesciences LLC ("Edwards") had contributed in part to the invention of the Tiara™ and awarded to Edwards co-entitlement rights to the disputed Tiara™...
2021-05-20 4:05 PM EDT
Neovasc to Sponsor Symposium on Reducer at EuroPCR
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 13, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ ("Reducer"), highlighting its easy integration into current cardiovascular and microvascular disease treatments. The symposium titled, "Latest clinical evidence and practical aspects to start Reducer therapy in your center," will be...
2021-05-13 9:35 AM EDT
Neovasc Announces First Patient Enrollment in COSIMA Trial
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina ("COSIMA") trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society ("CCS") Class IV angina on a daily...
2021-05-10 9:05 AM EDT